Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.41 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863864 | 0.90 | PIK3CD (0.45) | PIK3CDMAT2APIK3R2PIK3CGL3MBTL1 | |
| SCHEMBL864891 | 0.81 | PIK3CD (0.40) | PIK3CDMAT2AIDH1 | |
| SCHEMBL864269 | 0.81 | PIK3R2 (0.39) | PIK3CDMAT2APIK3R2IDH1 | |
| SCHEMBL15184821 | 0.80 | PIK3CD (0.50) | PIK3CDPIK3R2PIK3CG | |
| SCHEMBL863375 | 0.77 | PIK3CD (0.45) | PIK3CDPIK3CGIDH1 | |
| SCHEMBL863374 | 0.77 | PIK3CD (0.45) | PIK3CDPIK3CGIDH1 | |
| SCHEMBL863673 | 0.77 | PIK3CD (0.43) | PIK3CDPIK3R2PIK3CGL3MBTL1IDH1 | |
| SCHEMBL865314 | 0.76 | RAB9A (0.42) | PIK3CD | |
| SCHEMBL864898 | 0.76 | PIK3CD (0.45) | PIK3CDPIK3R2PIK3CG | |
| SCHEMBL864899 | 0.76 | PIK3CD (0.45) | PIK3CDPIK3R2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885MAT2A 4165/4885PIK3R2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.